The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development ...

CONSHOHOCKEN, Pa. - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biotech company with a market capitalization of $7.27 billion and strong financial health indicators according to InvestingPro data, ...

CONSHOHOCKEN, Pa. - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biotech company with a market capitalization of $7.27 billion and strong financial health indicators according to InvestingPro ...

Madrigal Pharmaceuticals (MDGL) announced it has appointed Jacqualyn Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Effectively assess a stock ...

March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...

CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...

Madrigal Pharmaceuticals has a 12 month low of $189.00 and a 12 month high of $377.46. Madrigal Pharmaceuticals ( NASDAQ:MDGL – Get Free Report ) last posted its earnings results on Wednesday ...

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) had its price objective lifted by stock analysts at Citigroup from $378.00 to $469.00 in a note issued to investors on Thursday ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges.

New York Mets utility infielder Nick Madrigal will soon undergo shoulder surgery and likely miss the entirety of the upcoming 2025 season, manager Carlos Mendoza told reporters on Friday.